Drug Database
Back to search

Belgium· BE-AMP-SAM462631-00

Incruse Ellipta 55 µg

A umeclidinium bromide product containing umeclidinium bromide, registered in Belgium by GlaxoSmithKline Trading Services. The same ATC class is registered in 12 of our 19 countries.

ATC R03BB07

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedIncruse Ellipta 55 µgATCR03BB07REGISTER NO.BE-AMP-SAM462631-00PACKS LISTED3CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about umeclidinium bromideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Umeclidinium bromide is registered in 12 of 19 countries.

Countries holding a registration under ATC R03BB07 (umeclidinium bromide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search umeclidinium bromide products by name

Umeclidinium bromide · ATC R03BB07

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of umeclidinium bromide costs, country by country.

Normalised to the WHO defined daily dose (55 mcg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Umeclidinium bromide · price per daily dose (55 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.57
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Umeclidinium Bromide
Manufacturer
GlaxoSmithKline Trading Services
Country
Belgium (BE)
ATC code
R03BB07
ATC class
Umeclidinium bromide
Defined daily dose
55 mcg, Inhal
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

2 priced
  • be_apb
    7712862
  • be_apb
    3270410
    EUR 101.91
  • be_apb
    3270402
    EUR 43.12

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

114 interactions on record for umeclidinium bromide.

Graded by severity as the source publishes them — 113 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check umeclidinium bromide against other medicinesHow interaction checks work

Umeclidinium bromide · interactions on record

114 records

  • 113 moderate
  • 1 minor

Most severe, free to view

  • DicycloverineA03AA07moderate
  • PropanthelineA03AB05moderate
  • MepenzolateA03AB12moderate
  • TrospiumA03AB20moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Umeclidinium bromide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All umeclidinium bromide products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Incruse Ellipta, Rolufta Ellipta
  • Liechtenstein · Incruse Ellipta, Rolufta Ellipta
  • Norway · Incruse Ellipta, Rolufta Ellipta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a655c690-33b3-49a0-b85e-3ef025cbda84
GET /v1/drugs/a655c690-33b3-49a0-b85e-3ef025cbda84?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Inhalation powder, pre-dispensed",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Incruse Ellipta 55 µg",
  "name_fr": "Incruse Ellipta 55 µg",
  "name_nl": "Incruse Ellipta 55 µg",
  "amp_code": "SAM462631-00",
  "strengths": [
    "65.0000",
    "65.0000",
    "55.0000",
    "55.0000",
    "12.5000"
  ],
  "pack_count": 3,
  "substances": [
    "Umeclidinium Bromide",
    "Umeclidinium",
    "Lactose Monohydrate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Umeclidinium Bromide",
  "authorisation_numbers": [
    "EU/1/14/922/001",
    "EU/1/14/922/002",
    "EU/1/14/922/003"
  ]
}
API referenceMCP serverPlans

See everything about umeclidinium bromide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console